16
Disclosures
Jan 8, 2026 — Apr 17, 2026
Date Range
GROWTH
Market Segment
Pharmaceutical
Sector

Disclosures

DateTypeHeadlinePDF
Apr 17 Other GNI Group to Seek Shareholder Approval for Gyre Therapeutics Acquisition Plan PDF
Mar 31 Other GNI Group Forecasts Revenue for FY2026 Despite Uncertainties PDF
Mar 31 M&A GNI Group Posts Record Revenue, Expands Medical Tech Segment PDF
Mar 30 Other GNI Group Posts Full Year Loss; Ownership Ratios Stable PDF
Mar 27 Other GNI Group: Appoints New External Director Amid Board Reorganization PDF
Mar 26 Earnings GNI Group: Reports FY2025 Earnings Presentation: Revenue of 400 million PDF
Mar 24 Other GNI Group: Files NDA for Liver Fibrosis Drug F351 in China PDF
Mar 18 Admin GNI Group: Confirms F351 Receives Priority Review in China; Set to Submit Formal NDA Soon PDF
Mar 13 M&A Forecasts $400M-$632M Revenue Over Five Years for F351 Treatment PDF
Feb 13 Earnings GNI Group Delays FY26 Earnings Forecast and Briefing Due to Fair Disclosure Concerns PDF
Feb 13 Other GNI Group Reports Significant Earnings Decline in Q4 2025 PDF
Feb 13 Earnings Gni Group Ltd. Reports FY25 Revenue of 26.8 billion, Up 14% PDF
Feb 12 Forecast GNI Group Updates on Overseas Acquisitions and Clinical Trials PDF
Jan 23 Forecast Earnings Forecast Downward Revision PDF
Jan 9 M&A GNI Group acquires ZOO LABO, expands dental tech operations PDF
Jan 8 Admin GNI Group Subsidiary Cullgen to Attend J.P. Morgan Healthcare Conference in San Francisco PDF

Disclosure Types

Other: 6 M&A: 3 Earnings: 3 Admin: 2 Forecast: 2